

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis — Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris ☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua ☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis ☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy ☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____
 Description _____
 Date of Diagnosis _____
 Has a TB test been performed? ☐ Yes ☐ No
 Does the patient have an active infection? ☐ Yes ☐ No
 Start Date _____ Review Date _____

Additional Information

Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____
 Additional Comments _____
 Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

Medication	Strength	Dose & Directions	Qty/Refills
<input type="checkbox"/> Cimzia®	Cimzia Starter Kit (6 prefilled syringes)	<input type="checkbox"/> <u>Loading Dose</u> : Inject 400mg SC (2 prefilled syringes) initially and at weeks 2 and 4.	Quantity: 1 Kit Refills: 0
<input type="checkbox"/> Cimzia®	<input type="checkbox"/> 200 mg/1 mL Prefilled Syringe <input type="checkbox"/> 200 mg Vial	<u>Psoriasis Maintenance Dose</u> : <input type="checkbox"/> 400 mg (given as 2 SC of 200 mg each) every other week. <input type="checkbox"/> 200 mg SC every other week. <u>Psoriatic Arthritis Maintenance Dose</u> : <input type="checkbox"/> 200 mg SC every other week. <input type="checkbox"/> 400 mg (given as 2 SC of 200 mg each) every 4 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> Sensoready® pen 150 mg/mL injection <input type="checkbox"/> Prefilled syringe 150 mg/mL injection	<input type="checkbox"/> <u>Psoriasis Loading Dose</u> : Inject 300 mg (two injections) SC at weeks 0, 1, 2, 3 and 4 (0 refills). <input type="checkbox"/> <u>Psoriasis Maintenance Dose</u> : Inject 300 mg (two injections) SC every 4 weeks. <input type="checkbox"/> <u>Psoriatic Arthritis Loading Dose</u> : (if needed): 150 mg SC at weeks 0,1,2,3, and 4 (0 refills). <input type="checkbox"/> <u>Psoriatic Arthritis Maintenance Dose</u> : 150mg SC every 4 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Enbrel®	<input type="checkbox"/> 50 mg/mL Sureclick™ Autoinjector <input type="checkbox"/> 50 mg/mL Prefilled Syringe <input type="checkbox"/> 50 mg/mL Enbrel Mini™ prefilled cartridge for use with the AutoTouch™ reusable autoinjector only (Prescriber MUST supply). Avella/Briova does not order the autoinjector. <input type="checkbox"/> 25 mg/0.5 mL Prefilled Syringe <input type="checkbox"/> 25 mg vial	<input type="checkbox"/> <u>Psoriasis Induction Dose</u> : Inject 50 mg SC TWICE a week (3 to 4 days apart) for 3 months, then maintenance dosing (8 pens, 2 refills). <input type="checkbox"/> <u>Psoriasis Maintenance Dose</u> : Inject 50 mg SC ONCE a week. <input type="checkbox"/> <u>Psoriatic Arthritis Dose</u> : Inject 50 mg SC ONCE a week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.


Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.

Specialty Pharmacy Enrollment Form
 Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

Please complete the following or **send patient demographic sheet**

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)
Diagnosis — Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris ☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua ☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis ☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy ☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____
 Description _____
 Date of Diagnosis _____
 Has a TB test been performed? ☐ Yes ☐ No
 Does the patient have an active infection? ☐ Yes ☐ No
 Start Date _____ Review Date _____

Additional Information

Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____

 Additional Comments _____

 Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Humira®	<input type="checkbox"/> Psoriasis 80 mg/0.8 mL and 40 mg/0.4 mL Starter Package Citrate Free	<input type="checkbox"/> <u>Psoriasis Induction Dose</u> : Inject 80 mg SC on day 1, followed by 40 mg SC on day 8, then 40 mg every other week.	Quantity: 1 Package Refills: 0
<input type="checkbox"/> Humira®	<input type="checkbox"/> Hidradenitis Suppurativa 80 mg/0.8 mL Starter Package Citrate Free	<input type="checkbox"/> <u>Hidradenitis Suppurativa Induction Dose</u> : Inject SC 160mg Day 1, then 80mg two weeks later (Day 15), then 40mg on Day 29 and subsequent doses.	Quantity: 1 Package Refills: 0
<input type="checkbox"/> Humira®	<input type="checkbox"/> 40 mg/0.4 mL Pen Citrate Free <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe Citrate Free <input type="checkbox"/> Other: _____	<input type="checkbox"/> <u>Psoriasis/Psoriatic Arthritis Maintenance Dose</u> : Inject 40mg SC every other week. <input type="checkbox"/> <u>Hidradenitis Suppurativa Maintenance Dose</u> : Inject 40 mg SC every week. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Ilumya™	100 mg/mL Prefilled Syringe	<input type="checkbox"/> <u>Psoriasis Induction Dose</u> : Inject one pre-filled syringe (100 mg) SC at weeks 0 and 4, then maintenance dosing (2 syringes, no refills). <input type="checkbox"/> <u>Psoriasis Maintenance Dose</u> : Inject one pre-filled syringe (100 mg) SC every 12 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Inflectra®	100 mg vial	<input type="checkbox"/> <u>Induction Dose</u> : Infuse 5 mg/kg (Dose = _____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> <u>Maintenance Dose</u> : Infuse at 5 mg/kg (Dose = _____mg) IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Orencia®	<input type="checkbox"/> 125 mg/mL Prefilled Syringe <input type="checkbox"/> 125mg/mL ClickJect Autoinjector <input type="checkbox"/> 250 mg vial <input type="checkbox"/> Other: _____	Inject 125 mg SC once weekly. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.

Specialty Pharmacy Enrollment Form
 Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

Please complete the following or **send patient demographic sheet**

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)
Diagnosis — Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris ☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua ☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis ☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy ☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____
 Description _____
 Date of Diagnosis _____
 Has a TB test been performed? ☐ Yes ☐ No
 Does the patient have an active infection? ☐ Yes ☐ No
 Start Date _____ Review Date _____

Additional Information

Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in
 Allergies _____
 Lab Data _____
 Prior Therapies _____
 Concomitant Medications _____

 Additional Comments _____

 Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Otezla®	Titration Starter Pack	Day 1: 10 mg PO in the morning. Day 2: 10 mg PO in the morning and 10 mg PO in the evening. Day 3: 10 mg PO in the morning and 20 mg PO in the evening. Day 4: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 6 and thereafter: 30 mg PO twice daily.	Quantity: 1 Pack Refills: 0
<input type="checkbox"/> Otezla®	30 mg tablet	<input type="checkbox"/> Maintenance Dose: 30 mg tablet PO twice daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Remicade®	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse 5 mg/kg (Dose = _____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter (0 refills). <input type="checkbox"/> Maintenance Dose: Infuse 5 mg/kg (Dose = _____mg) IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Renflexis®	100 mg Vial	<input type="checkbox"/> Induction Dose: Infuse 5 mg/kg (Dose = _____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter (0 refills). <input type="checkbox"/> Maintenance Dose: Infuse 5 mg/kg (Dose = _____mg) IV every 8 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ # of 100 mg vial Refills: _____
<input type="checkbox"/> Siliq®	<input type="checkbox"/> 210 mg/1.5 mL single-dose prefilled syringe	Inject one prefilled syringe (210 mg) SC at weeks 0, 1 and 2, followed by one prefilled syringe (210 mg) every 2 weeks. Prescribers must be certified in the SILIQ REMS Program to prescribe SILIQ. Please visit the following REMS website to register before prescribing SILIQ: SILIQ REMS Website (https://siliqrems.com/SiliqUI/home.u)	Quantity: _____ Refills: _____
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 50 mg/0.5 mL SmartJect® Autoinjector <input type="checkbox"/> 50 mg/0.5 mL Prefilled Syringe	<input type="checkbox"/> Psoriatic Arthritis Dose: Inject 50 mg SC once a month. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Simponi Aria®	50 mg/4 mL in a single-dose vial	Psoriatic Arthritis Dosing: <input type="checkbox"/> Induction Dose: 2 mg/kg IV infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter (0 refills). <input type="checkbox"/> Maintenance Dose: 2 mg/kg IV infusion over 30 minutes every 8 weeks.	Quantity: _____ # of 50 mg vial Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.

Specialty Pharmacy Enrollment Form

 Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____
 Address _____
 Address 2 _____
 City, State, Zip _____
 Home Phone _____ Alternate Phone _____
 DOB _____ Last Four of SS# _____ Gender _____
 Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____
 DEA _____
 NPI _____
 Group/Hospital _____
 Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis — Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris ☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua ☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis ☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy ☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____
 Description _____

Date of Diagnosis _____

Has a TB test been performed? ☐ Yes ☐ No

Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ Review Date _____

Additional Information

Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in

Allergies _____

Lab Data _____

Prior Therapies _____

Concomitant Medications _____

Additional Comments _____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

<input type="checkbox"/> Skyrizi®	75 mg/0.83 mL prefilled syringe	<input type="checkbox"/> Psoriasis Induction Dose: Inject 150 mg (two injections) SC at Weeks 0 and 4, then maintenance dosing (0 refills). <input type="checkbox"/> Psoriasis Maintenance Dose: Inject 150mg (two injections) SC every 12 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45 mg/0.5 mL prefilled syringe <input type="checkbox"/> 90 mg/mL prefilled syringe	<input type="checkbox"/> For patients weighing ≤100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later (2 syringes, 0 refills). <input type="checkbox"/> For patients weighing >100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later (2 syringes, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject 45mg SC every 12 weeks. <input type="checkbox"/> Maintenance Dose: Inject 90mg SC every 12 weeks. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Taltz®	<input type="checkbox"/> 80 mg Single Dose Autoinjector <input type="checkbox"/> 80 mg Single Dose Prefilled Syringe	Psoriasis Induction Dosing: <input type="checkbox"/> Starting Dose: Inject SC two 80 mg injections on Day 1, then begin first induction dose 2 weeks later. <input type="checkbox"/> Induction Dose: Inject SC one 80 mg injection every 2 weeks (weeks 2-10). <input type="checkbox"/> Final Induction Dose: Inject SC one 80 mg injection (week 12). Psoriatic Arthritis Induction Dosing: <input type="checkbox"/> Induction Dose: 160mg SC at week 0. <input type="checkbox"/> Maintenance Dose: 80mg SC once every 4 weeks.	<input type="checkbox"/> 8 pens/syringes <input type="checkbox"/> 2 pens/syringes Quantity: _____ Refills: _____
<input type="checkbox"/> Tremfya®	<input type="checkbox"/> 100 mg/mL prefilled syringe <input type="checkbox"/> 100 mg/mL One-Press Injector	<input type="checkbox"/> Induction Dose: Inject 100mg SC at week 0 and week 4 (2 syringes/pens, 0 refills). <input type="checkbox"/> Maintenance Dose: Inject 100mg SC once every 8 weeks.	Quantity: _____ Refills: _____
<input type="checkbox"/> Xeljanz®	<input type="checkbox"/> 5 mg Tablet <input type="checkbox"/> 11 mg XR Tablet	<input type="checkbox"/> Take one 5 mg tablet PO twice daily. <input type="checkbox"/> Take one 11 mg tablet PO once daily. <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Other	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.